Therapeutic Outcome of Endocrine Disorders

Efficacy, Innovation and Quality of Life

  • Brian Stabler
  • Barry B. Bercu
Conference proceedings

DOI: 10.1007/978-1-4612-1230-0

Part of the Serono Symposia USA book series (SERONOSYMP)

Table of contents

  1. Front Matter
    Pages i-xvi
  2. Outcome Research in Pediatric Psychoendocrinology and Sexology

  3. Treatment of Growth Hormone Deficiency: Efficacy, Innovation and Quality of Life

    1. Front Matter
      Pages 7-7
    2. Paul V. Carroll, Emanuel R. Christ, Peter H. Sönksen
      Pages 9-20
    3. Ingela K. Wiklund, Ann E. Erling, Kerstin Albertsson-Wikland
      Pages 21-29
    4. David E. Sandberg, Margaret H. MacGillivray, Richard R. Clopper, Dana E. Alliger, Caroline Fung, Linda LeRoux
      Pages 38-52
    5. Ana Claudia Keselman, Alicia Susana Martínez, Liliana Pantano, César Bergadá, Juan Jorge Heinrich
      Pages 53-60
  4. Treatment of Turner Syndrome: Efficacy, Innovation and Quality of Life

    1. Front Matter
      Pages 61-61
    2. David Skuse, Dorothy Bishop, Kate Elgar, Elena Morris
      Pages 69-82
    3. Margaret H. MacGillivray, Tom Mazur
      Pages 83-97
  5. Treatment of Short, Non-Growth Hormone Deficiency: Efficacy, Innovation and Quality of Life

    1. Front Matter
      Pages 99-99
    2. Dennis Drotar, Jane R. Robinson
      Pages 110-118
    3. Jessica C. Roberts, Martha U. Barnard, Michael C. Roberts, Wayne V. Moore, Eric M. Vernberg, Jerome A. Grunt et al.
      Pages 119-130
    4. Ulla Wide Boman, Kerstin Albertsson-Wikland, Anders Möller
      Pages 131-136
  6. Treatment of Diabetes: Efficacy, Innovation and Quality of Life

About these proceedings

Introduction

Changes in the allocation of healthcare resources have raised issues related to the efficacy and outcomes of medical therapy and how such factors may be measured. The questions associated with the quality of life and functional capability of patients with chronic health conditions have been of special interest. Endocrine disorders have the potential for disrupting the general health and well-being of affected individuals and their families; thus they warrant serious attention. This symposium was convened in November 1997 at Palm Beach Gardens, Florida, to bring together medical, behavioral, and social scientists. The meeting fostered the presentation and discussion of the most current clinical research on the effects of various therapies on a wide range of endocrine disorders from diabetes to adrenal insufficiency and growth hormone deficiency. The participants, all noted national and international experts in their fields, focused their attention on both the biomedical value and effectiveness of treatment, as well as on the impact such treatments have on psychological states such as mood and cognition. Many presentations specifically emphasized the quality of life (QOL) indicators that now regu­ larly appear in many research protocols and reports. The pioneering work of two clinical researchers was a major highlight of the meeting and an Award of Recognition was presented to Robert Blizzard, M. D. , and John Money, Ph. D. , for their innovative and insightful work in pediatric endocrinology and psychosexual development.

Keywords

Diabetes growth growth hormone hormone hormone therapy

Editors and affiliations

  • Brian Stabler
    • 1
  • Barry B. Bercu
    • 2
  1. 1.Department of Psychiatry School of MedicineUniversity of North Carolina at Chapel HillChapel HillUSA
  2. 2.Department of Pediatrics College of MedicineUniversity of South Florida, All Children’s HospitalSt. PetersburgUSA

Bibliographic information

  • Copyright Information Springer-Verlag New York, Inc. 2000
  • Publisher Name Springer, New York, NY
  • eBook Packages Springer Book Archive
  • Print ISBN 978-1-4612-7052-2
  • Online ISBN 978-1-4612-1230-0